Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Retrieved on:
Monday, April 22, 2024
GRACE, Hyperglycemia, University, Patient, Syndrome, SBP, Adrenal insufficiency, Safety, NDA, Waist, Ann Arbor, Michigan, MD, Doctor of Philosophy, Vaginal bleeding, DSM-IV codes, Doctor of Pharmacy, Diabetes, Hypertension, Metabolism, Internal medicine, Endocrinology, Division, Deficit spending, DBP, Pharmaceutical industry
In the “open-label” phase, 152 patients with Cushing’s syndrome and either hypertension, hyperglycemia or both received relacorilant for 22 weeks.
Key Points:
- In the “open-label” phase, 152 patients with Cushing’s syndrome and either hypertension, hyperglycemia or both received relacorilant for 22 weeks.
- GRACE’s primary endpoint is maintenance of blood pressure control in the “randomized withdrawal” phase, with maintenance of glycemic control as the key secondary endpoint.
- Other key secondary and exploratory endpoints in the randomized withdrawal phase include changes in weight, waist circumference, cognitive impairment and Cushing’s Quality of Life score.
- Patients in the open-label phase exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints.